ALX Oncology Holdings has received orphan drug designation from the European Commission for the treatment of patients with gastric cancer. This ODD indication includes both gastric cancer and gastroesophageal junction adenocarcinoma. The U.S. Food and Drug Administration also granted ODD to evorpacept for the treatment of patients with GC as previously announced in January 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALXO:
- ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer
- Cantor Fitzgerald biotech/biopharma to hold analyst/industry conference call
- ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
- ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer